Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

BACKGROUND: Autoantibodies against the M-type phospholipase A2 receptor (PLA2R1)
are specific markers for primary membranous nephropathy (pMN) and anti-PLA2R1 serum …

The M-type phospholipase A2 receptor (PLA 2 R) is the major target antigen in idiopathic
membranous nephropathy with detectable autoantibodies in the serum of up to 70% of …

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults,
with an uncertain clinical outcome. The characterization of the phospholipase A 2 receptor …

M-type phospholipase A2 receptor (PLA2R) is the major target antigen in primary
membranous nephropathy (PMN). Previous studies have evaluated the diagnostic value of …

Membranous nephropathy (MN) is the most prevalent cause of nephrotic syndrome amongst
the non-diabetic adult population. A fifth of idiopathic nephrotic syndrome cases can be …

Anti-phospholipase A2 receptor antibody (PLA2R-Ab) is useful for affirming the diagnosis of
idiopathic membranous nephropathy (IMN). Time-resolved fluoroimmunoassay (TRFIA) is …

Background The M-type phospholipase A2 receptor (PLA2R) is a specific target autoantigen
identified in idiopathic membranous nephropathy (IMN). The autoantibody against PLA2R …

Background Membranous glomerulopathy, though typically a disease of adults, does occur
in children. Antiphospholipase A2 receptor (PLA2R) autoantibodies have recently been …

Background Phospholipase A2 receptor (PLA2R) has been identified as a major
autoantigen in primary membranous nephropathy (MN). We evaluated the association …